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compensatory mutationsAbstract
Whether a trade-off exists between robustness and evolvability is an important issue for 
protein evolution.  While traditional viewpoints have assumed that existing functions must be 
compromised by the evolution of novel activities, recent research has suggested that existing 
phenotypes can be robust to the evolution of novel protein functions.  Enzymes that are targets of 
antibiotics that are competitive inhibitors must evolve decreased drug affinity while maintaining 
their function and sustaining growth.  Utilizing a transgenic Saccharomyces cerevisiae model 
expressing the dihydrofolate reductase (DHFR) enzyme from the malarial parasite Plasmodium 
falciparum, we examine the robustness of growth rate to drug-resistance mutations.  We assay 
the growth rate and resistance of all 48 combinations of 6 DHFR point mutations associated with 
increased drug resistance in field isolates of the parasite. We observe no consistent relationship 
between growth and resistance phenotypes among the DHFR alleles.  The three evolutionary 
pathways that dominate DHFR evolution show that mutating with increased resistance can 
compensate for initial declines in growth rate from previously acquired mutations.  In other 
words, resistance mutations that occur later in evolutionary trajectories can compensate for the 
fitness consequences of earlier mutations.  Our results suggest that high levels of resistance may 
be selected for without necessarily jeopardizing overall fitness.Introduction
In protein evolution, the development of a new function is often thought to necessitate the 
deterioration of an existing function (Kondrashov 2005). Such potential trade-offs would 
constrain protein evolution and slow the emergence of new protein functions.  However, recent 
research has suggested that proteins may be phenotypically robust and capable of evolving novel 
functions without compromising existing activities (Aharoni et al. 2005, Tawfik 2005, 
Khersonsky et al. 2006). 
Enzymes that are targeted by competitive inhibitors must evolve decreased affinity for 
the antibiotic while maintaining their initial catalytic ability(s).  For example, enzymes in human 
pathogens such as Streptococcus, Staphylococus, and HIV have evolved decreased antibiotic 
susceptibility via a series of point mutations while maintaining their original functions  (e.g. 
Laible et al. 1989, Hackbarth et al. 1995, Berkhout 1999).  However, sometimes such resistance 
mutations impose fitness costs, as in the case of a ribosomal protein in Salmonella (Björkman et 
al. 1998, Maisnier-Paitin et al. 2002, Maisnier-Paitin and Andersson 2004). In view of the 
antibiotic “warfare” among organisms that began long before the onset of anthropogenic drug 
pressure, antibiotic resistance is not only a threat to human health, but also raises fundamental 
evolutionary questions (e.g. Maplestone et al. 1992, Currie et al. 1999).
  In order to understand whether phenotypic tradeoffs exist and how they affect protein 
evolution, we chose a well-characterized enzyme whose evolution has been recently shaped by 
antibiotic pressure.  Dihydrofolate reductase (DHFR) plays an important role in the folate 
pathway, helping to provide cofactors for several important cellular reactions including DNA 
synthesis (Nirmalan et al. 2002).  In Plasmodium falciparum, the parasite responsible for the 
deadliest form of malaria, DHFR is the target of antifolate drugs, which represent inexpensive and potentially effective malarial therapies (Schlitzer 2007).  Increased use of antifolate drugs, 
particularly pyrimethamine, has selected for antifolate resistant DHFR alleles.  Several mutations 
at the DHFR locus of P. falciparum are now associated with high-level pyrimethamine resistance 
in field isolates (e.g. Sirawaraporn et al. 1997, Ekland and Fidlock 2007, Mita et al. 2007).
  Using a transgenic Saccharomyces cerevisiae model of P. falciparum antifolate resistance 
(Sibley and Macreadie 2001), we explored the mutational landscape of pyrimethamine resistance 
in DHFR.  We followed the combinatorial strategy of Weinreich et al. (2006) and constructed all 
48 combinations of 6 mutations at 5 amino acid sites.  Each of these mutations is associated with 
pyrimethamine resistance and has been observed in combination with one or more of the other 5 
mutations in malarial field isolates (Foote et al. 1990, Sirawaraporn et al. 1997). We observe a 
single fitness maximum which population genetic simulations suggest is most likely to be 
accessible by a small number of mutational paths. These pathways exhibit compensatory 
evolution: initial resistance-conferring mutations decrease growth rate, however their effects are 
quickly compensated for by subsequent mutations.  Our results suggest that high levels of 
resistance may be selected for without necessarily jeopardizing overall fitness.Methods
Yeast Strain Construction
Carol Sibley of the University of Washington generously provided the GR7 shuttle 
vector, a derivative of the pRS314 yeast shuttle vector (Sikorski and Hieter 1989, Wooden et al. 
1997).   This vector contains the wild-type P. falciparum DHFR allele regulated by 600 base 
pairs from the promoter region of the S. cerevisiae DFR1 gene and by the 400 base pair 3' DFR1 
transcription and translation terminators. GR7 also includes the TRP1 yeast biosynthetic marker, 
and a yeast centromere sequence that maintains the plasmid at about one copy per cell (Hunt et 
al. 2005).
We constructed all 48 possible combinations of the 6 point mutations at 5 amino acid 
coding sites in DHFR (A16V, N51I, C59R, S108N/T, I164L) on the GR7 vector using the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, Cedar Creek TX).  The DHFR locus on 
each mutagenized plasmid was sequenced to verify the presence of the engineered mutations. 
  We used the S. cerevisiae strain TH5 (MATa leu2-3,112 trp1 ura3-52 dfr1::URA3 tup1; 
provided by Carol Sibley) to assay the level of pyrimethamine resistance conferred by each 
DHFR allele.  TH5 lacks DFR1, the yeast orthologue of the DHFR gene and, when not 
transformed with a functional DFR1 homolog, the strain requires media supplemented with 
100µg/mL deoxythymidine monophosphate (dTMP; Sigma-Alrich, St. Louis, MO) for growth.  
The tup1 mutation increases cellular permeability to dTMP (Wooden et al. 1997).  We 
transformed TH5 with each of the 48 alleles using the EZ Yeast Transformation Kit (Zymo, 
Orange CA), selecting for the presence of the GR7 vector on tryptophan dropout media (SC trp-) 
supplemented with 100µg/mL dTMP.Minimum Inhibitory Concentrations
Minimum inhibitory concentrations (MICs) for pyrimethamine were determined using a 
solid plate assay.  For each biological replicate of each strain, a colony was picked into 3 ml 
unsupplemented liquid YPD.  After 48 hours, we measured optical density (OD600), and each 
strain was serially diluted to a final OD600 of 0.002 (~1.2x104 cells/ml).  Five µl of each diluted 
strain (~60 cells) was spotted on plates containing either ethanol (negative control) or increasing 
concentrations of pyrimethamine. We used two biological replicates each with four technical 
replicates for each strain. The minimum inhibitory concentration (MIC) for each replicate was 
defined as the lowest concentration of pyrimethamine to fully inhibit growth.
Strains were initially assayed using a log10 scale of pyrimethamine concentrations, 
ranging from 10-9 to 10-4 M. To further resolve MIC values among strains, we used additional 
pyrimethamine concentrations (2.5 x 10-a, 5 x 10-a, and 7.5 x 10-a between each set of 
concentrations 10-(a+1) and 10-a) for all strains with MIC values higher than 10-6 M.  The full MIC 
data set is listed in Supplementary Table S4.
 
Growth Rate Measurements
Following Joseph and Hall (2004), we measured the growth rate of each strain in the 
presence various concentrations of pyrimethamine (0 M, 10-8 M, 10-7 M, 10-6 M, 10-5 M, 10-4 M) 
using a Bioscreen C microbiological workstation (Thermo Labsystems). For each biological 
replicate, we picked a colony from a solid media plate and inoculated a 5 ml liquid YPD culture.  
After 48 hours of shaking incubation at 30˚C, cultures were diluted to an optical density (OD600) 
of 0.01, or approximately 6 * 104 cells/mL.  Aliquots of 200 µl were transferred to microtiter plates for growth in the Bioscreen, and the optical density (OD600) was measured every 15 
minutes for 3 days. For each of at least 2 biological replicates per strain, we assayed at least 4 
technical replicates in each concentration of pyrimethamine.  Using code written in R, we 
calculated least-squares linear regressions for log absorbance versus time for a 3.25-hour sliding 
window over the length of the growth curve.  Growth rates represent the maximum regression 
coefficient among all sliding windows over length of the growth curve.  Growth rates of each 
allele in the absence of pyrimethamine are depicted in Supplementary Table S2.
IC50 calculations
  For each strain, we fit the following logarithmic curve to our growth rate versus 
pyrimethamine concentration data:
€ 
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                  (1)
where Gi is the growth rate of strain i, Ai is the maximum growth rate in the absence of 
pyrimethamine, bi is the pyrimethamine concentration where Gi is half of Ai, ci is a scaling 
parameter determining the shape of the logistic regression, and x is the log10 of the 
pyrimethamine concentration.  IC50 values for each strain represent the value of bi from 
nonlinear least-squares regressions.  Regression code was written in R. 
We determined the correlation between our calculated IC50 values and our observed 
MICs (Spearman’s rank correlation: P = 5.895 * 10-11, Figure S1).  For three DHFR alleles 
(C59R/S108N/I164L, N51I/S108N/I164L, N51I/C59R/S108N/I164L), statistically significant 
IC50 values could not be determined from our logistic regressions because we did not observe a significant decrease in growth rate over the range of pyrimethamine concentrations.  For these 
cases, we fit a linear model (IC50~MIC) to our resistance data and used this model to predict the 
IC50 values of the missing strains.  The complete IC50 data set is presented in Supplementary 
Table S3.
Calculation of accessible evolutionary trajectories
  Following previously established methodology (Weinreich et al. 2006, DePristo et al. 
2007, Lozovsky et al. 2009), we used the allele-specific resistance (IC50) data to analyze the 
mutational trajectories that are accessible to DHFR evolution.  Under a model where selection 
acts to increase pyrimethamine resistance, we assumed that the time to fixation or loss of a newly 
arising mutation is much shorter than the time between mutations (“strong selection/weak 
mutation;” Gillespie 1984).  As alleles with a single mutation do not segregate long enough to 
experience a second mutation, this model considers evolutionary trajectories with only single, 
positive mutational steps (see Weinreich et al. 2006 for a detailed description).  Following 
DePristo et al. (2007), we consider all potential positively selected single mutant neighbors, 
including reversions of previously fixed mutations.  We consider only mutations that increase 
resistance, assuming that probabilities (and thus rates) of fixation will be much higher for such 
mutations than for neutral mutations or those that decrease resistance. 
Because each fixation event is statistically independent of those occurring previously, 
The probability of moving from the low fitness wild type (wt) to an allele of a higher fitness, 
dhfr*, via mutational intermediates a, b, and c is given, as in Weinreich et al. (2006), by€ 
Pwt→dhfr* = Pwt→a ⋅ Pa→b ⋅ Pb→c ⋅ Pc→dhfr* .        (1)
We used two methods for estimating the probability of fixation (Pi→j) of the single mutant 
neighbor, j, of current allele i.  Under equal fixation probability, we assume that all favorable 
alleles have an equal probability of fixation.  Algebraically,
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1
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where Mi+ is the set of all single mutant neighbors of positive selective value.  
Under correlated fixation probability, we follow the extreme value theorem based 
approach of Weinreich et al. (2006) based on Orr (2002). This model assumes a correlation 
between the size of the selective increase (in our case, drug resistance) and its fixation 
probability. In particular,
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where ri is the fitness rank (based on IC50 value) of all alleles regardless of mutational 
adjacency.
In order to account for the effects of genome-specific mutational bias in Plasmodium 
falciparum, we weight the probability of each potential fixation by its mutational frequency 
according to the following equation:         (4)
where Pi→j is the equal or correlated transition probability as calculated above, and βi→j is the 
relative bias of the mutation necessary to produce allele j from allele i.  Daniel Neafsey (Broad 
Institute, Cambridge, MA) kindly provided a twelve-parameter mutation rate matrix based upon 
1073 intergenic SNPs in P. falciparum (see Table S3 in Lozovsky et al. 2009).  SNPs were 
identified using neighborhood quality standard (NQS) criteria.  Eligible SNPs had quality scores 
of at least Q20 for both alleles and did not occur in CpG dinucleotides.  The directionality of 
mutations was inferred based on simple parsimony with P. falciparum’s sister species, P. 
reichenowii.
  Probabilities of evolutionary trajectories and their corresponding confidence intervals 
were estimated using simulations run using PERL.  For each allele, we used the calculated IC50 
value and the corresponding standard error as the mean and standard deviation of a normal 
distribution defining the resistance distribution for each allele.  Using these IC50 distributions to 
probabilistically define mutational landscapes, we simulated 1000 mutational landscapes. We 
then simulated 1 million rounds of evolution on each landscape under both fixation models (see 
Lozovsky et al. 2009).  
Simulating landscapes and trajectories in this way allows the probability estimates to 
account for uncertainty in our resistance measurements.  As a result, many trajectories, regardless 
of their probability, occur on low-likelihood landscapes. We therefore report a set of consensus 
trajectories that occur on at least 85% of all landscapes.  Changing the percent of simulated 
landscapes on which a trajectory must occur only modestly changes the number of trajectories considered (95% threshold = 29; 85% threshold = 46; 50% threshold = 85).  However, it does not 
change the identity of the most frequent trajectories.
Mean trajectory probabilities (see Figure 3.3, Supplementary Table 3.S1) represent the 
mean frequency of each trajectory across the 1,000 simulated landscapes. Statistics were 
calculated using scripts written in R.Results
  In order to understand how various mutational combinations may affect the ability of 
strains to grow, we analyzed the growth rates of different genotypes in the absence of the 
antifolate drug (Supplementary Figure S1, Supplementary Table S2). Among the 48 genotypes, 
19 demonstrated no observable growth in the absence of pyrimethamine; we consider these 
alleles to be nonfunctional even though some demonstrate in vitro activity toward dihydrofolate 
(e.g. A16V; see Sirawaraporn et al. 1997). The 29 functional alleles have relative growth rates 
between 71-104% of the wild type. Among the 6 single-mutant neighbors of the wild-type 
sequence, 5 have statistically significantly lower growth rates than the wild type (based on non-
overlapping 95% confidence intervals; but see 00100 in Supplementary Figure S1). Only C59R 
has a non-significantly different growth rate.  In the yeast system, the wild type allele appears to 
be a fitness peak in the absence of drug pressure.
We next analyzed the pyrimethamine resistance levels of the 29 functional alleles 
(Supplementary Figure S2, Supplementary Table S3).  We define resistance as the Inhibitory 
Concentration 50 (IC50), which is the concentration of drug needed to reduce the strain’s growth 
rate by half (see Materials and Methods).  Consistent with previous resistance data from parasite 
field isolates, the quadruple mutant N51I/C59R/S108N/I164L exhibits the highest resistance, and 
triple mutants C59R/S108N/I164L and N51I/C59R/S108N also exhibit high levels of resistance 
(Sirawaraporn et al. 1997). ).  Likewise, S108N confers the highest resistance among single 
mutations.
The individual mutations have remarkably different effects on resistance (Table 1).  For 
example, while S108N increases pyrimethamine resistance 128 fold, replacing Ala with Val at 
site 16 reduces resistance on the vast majority of genetic backgrounds.  Mutations also differ in their ability to restore functionality to a nonfunctional genetic background (see Rescues, Table 
1).
Overall, we observe no clear association between resistance level and growth rate (Figure 
1).  Correlation analysis between growth rate and resistance levels suggests these two phenotypes 
are independent (Pearson correlation: P= 0.7589). This lack of association suggests phenotypic 
robustness in DHFR evolution in the genetic background of S. cerevisiae.  Further, neither 
growth rate nor pyrimethamine resistance is a simple function of the number of mutations 
present in a DHFR allele (Supplementary Figure S4).  Regression analyses between the number 
of mutations and either phenotype failed to yield a significant relationship (growth rate: adjusted 
R2 = 0.001994, P = 0.313; IC50: adjusted R2 = 0.05281, P = 0.121).  Our data indicates that only 
specific combinations of mutations are beneficial to either growth rate or resistance and that 
interactions between mutations strongly affect phenotype.
  In order to understand the effect of this mutational landscape on DHFR evolution, we 
simulated the evolution of pyrimethamine resistance following previously established 
methodology (Weinreich et al. 2006, DePristo et al. 2007, Lozovsky et al. 2009, see Methods).  
Assuming that the time between mutations is much longer than the time for fixation or loss of 
new mutations (Gillespie 1984, Orr 2002), our simulations move step-by-step through the 
mutational landscape adding or removing a single mutation at each point along a mutational 
trajectory. Given the relative likelihood of fixing a neutral or deleterious mutation under the 
intense selective pressure of antibiotics, we consider only positively selected mutational steps. As 
it is unclear how the level of resistance to pyrimethamine corresponds to fitness, we use two 
models to predict the probability of mutational fixations.  The equal fixation model assumes that 
all favorable steps are equally likely, whereas the correlated fixation model assumes that a mutation’s probability of fixation is proportional to the magnitude of the increase in resistance 
(Weinreich et al. 2006).  To compensate for mutational bias in the P. falciparum genome, we 
weight the frequency of the occurrence of mutations by the P. falciparum-specific relative 
mutation rates (see Materials and Methods above, and Table S3 in Lozovsky et al. 2009).
  While we observe 46 selectively accessible mutational trajectories (i.e. those in which 
each step results in an increase in resistance), DHFR evolution is actually highly predictable and 
dominated by a handful of trajectories. The ten most likely evolutionary trajectories, depicted in 
Figure 2, are observed between 84% and 99% of the time (Figure 3).  Further, over 80% of our 
simulations fix S108N first (Supplementary Figure S5) and all trajectories end at the global 
resistance maximum, the quadruple mutant, N51I/C59R/S108N/I164L.  Additionally, while 
many functional genotypes containing A16V have higher pyrimethamine resistances than the 
wild type, this mutation is not visited in any of the most frequent trajectories.  Perhaps because 
of its extremely detrimental effect on native DHFR function (Sirawaraporn et al. 1997), we 
observe that A16V is only favorable on 3 of the possible 24 genetic backgrounds (Table 1).
  The three most likely evolutionary trajectories illustrate how resistance can evolve 
without necessarily compromising growth rate.  Figure 4 depicts the growth rate and resistance 
level of alleles at each mutational step in these pathways.  The right hand plots for each pathway 
demonstrate how resistance continuously increases at each step in these paths.  However, the left 
hand plots show that growth rate fluctuates along the path to higher resistance.  Linear regression 
models reveal that mutational step has no significant effect on growth rate over the course of 
these three trajectories (adjusted R2 < 0.05 and P > 0.35 for all three regressions).  In each 
trajectory, subsequent resistance increasing mutations quickly compensate for the growth rate 
effect of the initial fixation (S108N).Discussion
We describe the growth rate and pyrimethamine resistance mutational landscapes of 
DHFR and find growth rate remarkably robust to mutations that increase resistance.  Correlation 
analyses and evolutionary simulations reveal that, in the yeast model system, resistance and 
growth rate phenotypes freely associate.  Because interactions between mutations seem to play a 
large role in determining both growth rate and resistance levels, the phenotype of alleles with 
multiple mutations is difficult to predict based on the phenotypic effects of the individual 
mutations alone
In general, there is a complex relationship between different DHFR genotypes’ in vitro 
biochemical properties and their organismal phenotypes.  For example, the pyrimethamine 
affinity (Ki) of the individual DHFR alleles does predict the level of resistance of each strain 
(Supplementary Figure S6; Pearson correlation: 0.89, P = 0.0001).  However, there are 
exceptions. Some mutations that increase pyrimethamine affinity (decrease Ki) still increase 
resistance (e.g. N51I and I164L; see Supplementary Figure S2 and Sirawaraporn et al. 1997). 
Even more surprisingly, there is no significant correlation between the native activity of different 
DHFR alleles and their growth rate (Supplementary Figure S6).  For example, while the activity 
(kcat/KM) of wild type and N51I/C59R/S108N alleles for dihydrofolate differ by nearly 40-fold, 
they grow at the same rate in the absence of pyrimethamine. The well-established concave 
relationship between fitness and enzyme activity for pathway enzymes may explain some of the 
absence of correlation (Hartl et al. 1985); however, this relationship cannot explain cases in 
which one allele has a higher activity but a lower growth rate than another (e.g., compare N51I 
with C59R/S108N; Figure 1, Sirawaraporn et al. 1997).  We hypothesize that these mutations affect other protein properties, including degradation, aggregation, and folding, which may also 
impact growth rate.
Previous research suggests that mode of binding between drug and target may dictate the 
tradeoff between resistance and native enzyme function (Berkhout et al. 1999, Tawfik 2005).  
Drugs that bind directly in the active site may impose greater tradeoffs than drugs that bind` 
external to the catalytic core (Berkhout 1999, Tawfik 2005).  Applying this model, antifolate 
drugs such as pyrimethamine, which bind directly in DHFR’s active site and interact with key 
residues involved in dihydrofolate binding (Yuvaniyama et al. 2003), should impose a strong 
tradeoff in the development of pyrimethamine resistance.  However, while the addition of these 
mutations significantly decreases the native enzyme activity toward dihydrofolate (Sirawaraporn 
et al. 1997), they do not have the same, consistent impact on growth rate.  In total, our data 
suggests that organismic fitness, as determined by growth rate, may be even more robust than 
biochemical parameters alone would indicate.
Despite the additional constraint of maintaining its native enzymatic function, DHFR’s 
evolutionary landscape is similar in one important aspect to that of β–lactamase (Weinreich et al. 
2006). As in Weinreich et al. (2006), our simulation results also suggest that protein evolution 
may be highly biased toward a small number of mutational trajectories.  In both cases, between 
two and four trajectories are likely to occur at least 50% of the time, independent of the fixation 
model used.  
Surprisingly, the DHFR landscape may be more accessible to natural selection than the 
β–lactamase landscape.  To make these landscapes comparable, we limit the mutational 
landscape to those mutations comprising the global fitness maximum (i.e. five for β–lactamase and four for DHFR).  Further, we consider mutational trajectories that are comprised solely of 
forward mutations as these may cover as much as 99% of the trajectory probability space 
(DePristo et al. 2007).  Weinreich et al. (2006) observe that 15% to 32.5% (18 to 39 of 120) of 
forward trajectories are accessible while we observe that 58% (14 of 24) of potential forward 
trajectories are accessible. The β–lactamase landscape appears more constrained even if the 
landscape is restricted to the four sites that are likely to fix first (9 of 24 or 37.5%).  As growth 
rate appears to be robust to mutations increasing resistance, our results suggest that the 
maintenance of an existing enzymatic function does not significantly impact the evolution of 
nonnative protein functions.
Our results from a yeast system for malarial DHFR are similar to those from a system 
developed for Escherichia coli (Chusacultanachai et al. 2002). As explored by Lozovsky et al. 
(2009), the favored evolutionary pathways in the E. coli system are congruent with those in yeast 
(heavy lines in Figure 2).  Like in the yeast system, the DHFR alleles in E. coli show no 
consistent correlation with growth rate in the absence of drug (P = 0.81). 
However, the two systems exhibit some notable differences. For example, the variance in 
growth rate among strains carrying the various DHFR alleles is ~10 times greater in E. coli than 
in yeast. The narrower range of growth rates is reflected in the smaller effects of individual 
replacements. In E. coli, replacing the triple mutant N51I/C59R/S108N with the quadruple 
mutant N51I/C59R/S108N/I164L reduces growth rate by about 40 percent, and replacing C59R/
S108N/I164L with quadruple mutant reduces it by about 32 percent. In yeast, by contrast, the 
former mutation reduces growth rate by only 14 percent (Figure 4C and D, Figure 4E and F), and 
the latter mutation has no detectable effect though the standard error bars are quite large (Figure 
4A and B). The general amelioration of the growth rate effects of the DHFR allele may reflect a lower requirement for DHFR activity in yeast relative to E. coli.  If it exists, this lower DHFR 
activity requirement may be due to generalized reasons in the metabolic economy of yeast, or it 
may be due to some specific enzyme such as a relative increase in the activity of GTP-
cyclohydrolase I, which in yeast is encoded in FOL2 (Nardese et al., 1996). This is the first 
enzyme in the biosynthetic pathway for folic acid, and in P. falciparum, Nair et al. (2008) have 
shown that copy-number polymorphisms can reduce the growth-rate effects of DHFR mutants.
Our results may lend insight into the evolution of P. falciparum DHFR in nature.  For 
example, while the vast majority of our constructed alleles are not observed in malarial field 
isolates, all of the alleles present in each of the three most likely mutational trajectories have 
been isolated from patients (Sirawaraporn et al. 1997).  We also confirm the importance of the 
S108N mutation, which has long been speculated to be the first mutation fixed in DHFR 
resistance evolution based predominantly on its biophysical importance (Sirawaraporn et al. 
1997, Yuvaniyama et al. 2003).  In light of the challenge of culturing and genetically 
manipulating the parasite itself, the use of this and other model systems may provide powerful 
insights into combating the threat of drug resistance in Plasmodium falciparum.
Negative tradeoffs between growth rate and resistance at drug targets provide hope in 
combating the evolution of antibiotic resistance.  If large negative tradeoffs exist, one might 
imagine restoring drug susceptibility by relaxing drug pressure (Andersson 2006).  However, 
upon the relaxation of drug pressure, resistance phenotypes are likely to be maintained while 
additional mutations compensate for their fitness consequences (Maisnier-Paitin et al. 2002, Nair 
et al. 2008).  Our results are consistent with these findings and show that resistance-conferring 
mutations themselves can compensate for the fitness consequences of initial mutations (Figure 
4).  Together, these results suggest that once initially selected for, drug resistant genotypes may remain at high frequencies in populations even in the absence of antibiotic pressure.  Resistance 
prevention may still provide the best strategies in combating antibiotic resistance (Palumbi 
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malarial DHFR-TS structures. Nat Struct Biol. 10: 357-365.Figure 1.  A plot of resistance (IC50) versus growth rate in the absence of pyrimethamine for 
each of the 29 functional DHFR alleles.  No significant correlation exists between these two 
phenotypes (Pearson correlation: P = 0.7512).Figure 2. Ten most frequent evolutionary pathways leading from the wild type to the quadruple 
mutant using the correlated fixation model.  According to our model, evolution of pyrimethamine 
resistance follows one of these 10 pathways nearly 99% of the time. Five digit numbers indicate 
allelic states at each evolutionary step where each digit corresponds to an amino acid site (from 
left to right: 16, 51, 59, 108, 164).  Wild type states are depicted as 0 while mutant states are 
depicted as 1 or 2 (site 108: S=0, N=1, T=2).  Bold arrows indicate the three most likely 
pathways and the thickest arrows depicting the most likely path.Figure 3. Probability density function (pdf) for ten evolutionary pathways of greatest frequency.  
The solid line depicts the pdf based on equal fixation probabilities while the dashed line depicts 
the pdf from correlated fixation probability. Landscapes were simulated based upon IC50 data in 
Table S3.  Pathways are ranked according to mean frequency.  Error bars represent 95% 
confidence intervals.Figure 4.  Growth rates (left) and resistance values (right) of alleles at each step in the three most 
likely evolutionary pathways.  Plots in the same row (A and B, C and D, E and F) display data 
from the same trajectory.  Alleles at each step in the mutational trajectories are displayed above 
the plots. Five digit numbers indicate allelic states at each evolutionary step where each digit 
corresponds to an amino acid site (from left to right: 16, 51, 59, 108, 164).  Wild type states are 
depicted as 0 while mutant states are depicted as 1 or 2 (site 108: S=0, N=1, T=2).    Rates 
represent growth in the absence of drug and are relative to the wild type growth rate.  Error bars 
represent 95% confidence intervals.Table 1. Summary of mutational effects on pyrimethamine resistance (IC50).
  Alleles upon which the mutational effect is
Mutation  Positivea  Negativea  Negligible  Mean 
Proportional Increaseb  Rescuesc
A16V  3  20  1
  0.28d 2
N51I  13  3  8
  1.45  2
C59R  12  1  11
  3.37  5
S108N  7  3  6
  128.72  0
S108T  12  2  2
  52.74  4
I164L  10  7  7
  2.51  3
a Based on non-overlapping IC50 95% confidence intervals.
b Does not include genetic backgrounds where the mutation is deleterious or those where the 
mutation rescues the ability to grow in unsupplemented YPD (see below).c Number of genetic backgrounds where the presence of the mutation restores the ability to grow 
in unsupplemented YPD.
a Based on one genetic background (C59R + I164L).Supplementary Figure S1. Relative growth rate for DHFR alleles.  19 of 48 alleles have no 
measurable growth in the absence of pyrimethamine and are not depicted.  Alleles are designated 
by code corresponding to the genotype of allele at each of the 5 amino acid sites.  0 indicates the 
wild type state where a 1 or 2 indicates a mutant state.  Sites are designated from left to right as 
follows: 16, 51, 59, 108 (1=S108N, 2 = S108T), 164.  The chart groups alleles together alleles 
with similar numbers of mutations. Error bars indicate 95% confidence intervals.Supplementary Figure S2. Resistance measurements (Inhibitory concentration 50 values) for 29 
DHFR alleles with non-zero growth rates in unsupplemented YPD.  Alleles are designated as in 
Figure 1 and are grouped according to number of mutations.  Error bars indicate 95% confidence 
intervals as calculated from IC50 standard errors. Supplementary Figure S3. Correlation between IC50 values and median MIC values for DHFR 
alleles (Pearson correlation: P = 4.383x10-11). Supplementary Figure S4. Resistance and growth rate phenotypes as a function of the number 
mutations present in each of the 29 functional DHFR alleles.  P values shown indicate 
significance level of Spearman’s rank correlations.  Inclusion of data points representing the 19 
nonfunctional alleles does not affect the significance of the correlation (resistance: P = 0.93; 
growth rate: P = 0.12).Supplementary Figure S5. Frequency of observing a pathway with a given starting mutation 
under the correlated fixation probability model.  Any given evolutionary pathway has over an 
80% chance of beginning with the S108N fixation. Supplementary Figure S6. Correlation between cellular and biochemical parameters.  Left: 
resistance (IC50) strongly correlates with binding affinity (Ki; Pearson correlation: P = 0.0001).  
Right: we observe no relationship between relative growth rate and DHFR activity (kcat/KM; 
Pearson correlation: P = 0.68). Kinetic data from Sirawiraporn et al. (1997).Supplementary Table S1. Complete list of observed trajectories, their mean realization 
probability and their standard deviations (SD).
  Trajectorya  Correlated Fixation (SD)
  Equal Fixation (SD)
00000 00010 00110 00111 01111  0.38864774 (0.171318377)
  0.139065694 (0.045363128)
00000 00010 00110 01110 01111  0.27074593 (0.160082718)
  0.106254998 (0.044355438)
00000 00010 01010 01110 01111  0.189791833 (0.040007198)
  0.271743332 (0.061614977)
00000 01000 01010 01110 01111  0.079975918 (0.013273888)
  0.128010183
  0.030355251
00000 00020 00010 00110 00111 01111  0.016516645 (0.008301096)
  0.02311604 (0.007519723)
00000 00020 00010 00110 01110 01111  0.011797008 (0.00791432)
  0.017664455 (0.007375537)
00000 00001 01001 01011 01111  0.008141736 (0.00174267)
  0.020511821 (0.002937899)
00000 00020 00010 01010 01110 01111  0.008027757 (0.002241096)
  0.045180634 (0.010239161)
00000 00100 00110 00111 01111  0.006926104 (0.003389162)
  0.045933575 (0.014961438)
00000 00100 00110 01110 01111  0.004857461 (0.003097629)
  0.03508894 (0.014646731)
00000 00001 00021 00121 00111 01111  0.004814334 (0.000990451)
  0.006327484 (0.000904467)
00000 00001 00101 00111 01111  0.002563139 (0.001308486)
  0.019689391 (0.00486)00000 01000 01001 01011 01111  0.002396596 (0.000436389)
  0.013328362 (0.001579775)
00000 00001 01001 01011 01010 01110 01111  0.001653416 (0.000329423)
  0.026329258 (0.00650709)
00000 00001 00021 00121 01121 01111  0.000819277 (0.000538871)
  0.00235375 (0.001608579)
00000 01000 01001 01011 01010 01110 01111  0.000487163 (8.71E-05)
  0.017142423
  0.004073945
00000 00100 01100 01110 01111  0.000362569 (0.000126308)
  0.010866028 (0.003985112)
00000 00100 00101 00111 01111  0.000325176 (0.000101816)
  0.009479434 (0.001247647)
00000 00001 00021 00020 00010 00110 00111 01111  0.000316136 (0.000169316)
  0.003514894 (0.001241488)
00000 00001 00021 00020 00010 00110 01110 01111  0.000231112 (0.000169306)
  0.002676097 (0.001149997)
00000 00001 00101 00121 00111 01111  0.000171388 (8.73E-05)
  0.00207069 (0.000513102)
00000 00001 00021 00020 00010 01010 01110 01111  0.00015587 (6.02E-05)
  0.006851339 (0.001687122)
00000 00001 00101 10101 10121 00121 00111 01111  9.20E-05 (4.31E-05)
  0.005133802 (0.001276927)
00000 00001 00101 01101 01111  4.91E-05 (2.23E-05)
  0.002541424 (0.000664341)
00000 00001 00101 00121 01121 01111  2.88E-05 (2.32E-05)
  0.000778544 (0.000566009)
00000 00100 00101 00121 00111 01111  2.16E-05 (8.12E-06)
  0.000997285 (0.000135864)00000 00001 00101 10101 10121 11121 01121 01111  2.04E-05 (1.17E-05)
  0.008092047 (0.005902088)
00000 00001 00101 10101 10121 00121 01121 01111  1.54E-05 (1.26E-05)
  0.001931447 (0.001408153)
00000 00100 01100 01000 01010 01110 01111  1.37E-05 (8.27E-06)
  0.009201777 (0.003962728)
00000 00100 00101 10101 10121 00121 00111 01111  1.26E-05 (5.94E-06)
  0.002474674 (0.000335251)
00000 00100 01100 01101 01111  7.84E-06 (4.00E-06)
  0.001521393 (0.000498001)
00000 00100 00101 01101 01111  6.55E-06 (3.43E-06)
  0.001224385 (0.000193639)
00000 00001 00101 01101 01121 01111  3.89E-06 (2.97E-06)
  0.000366587 (0.000267659)
00000 00100 00101 00121 01121 01111  3.79E-06 (3.52E-06)
  0.00037406 (0.000257987)
00000 00100 00101 10101 10121 11121 01121 01111  n.o.
  0.003880744 (0.002674073)
00000 00001 00101 01101 01001 01011 01010 01110 01111  n.o.
  0.001291951 (0.000428994)
00000 00100 01100 01000 01001 01011 01010 01110 01111  n.o.
  0.001233807 (0.000533438)
00000 00001 00101 01101 01001 01011 01111  n.o.
  0.001003871 (0.000261178)
00000 00100 01100 01000 01001 01011 01111  n.o.
  0.00095229 (0.000362137)
00000 00100 00101 10101 10121 00121 01121 01111  n.o.
  0.0009268 (0.000638005)
00000 00100 01100 01101 01001 01011 01010 01110 01111  n.o.
  0.00076847 (0.000289686)00000 00100 00101 01101 01001 01011 01010 01110 01111  n.o.
  0.000622212 (0.000161266)
00000 00100 01100 01101 01001 01011 01111  n.o.
  0.000602881 (0.000199068)
00000 00100 00101 01101 01001 01011 01111  n.o.
  0.000483708 (7.63E-05)
00000 00100 01100 01101 01121 01111  n.o.
  0.000220762 (0.000176643)
00000 00100 00101 01101 01121 01111  n.o.
  0.000176257 (0.000122652)
aAlleles are designated by code corresponding to the genotype of allele at each of the 5 amino 
acid sites.  0 indicates the wild type state where a 1 or 2 indicates a mutant state.  Sites are 
designated from left to right as follows: 16, 51, 59, 108 (1=S108N, 2 = S108T), 164.
bNot observed.Supplementary Table S2. Growth rate of 29 functional DHFR alleles in the absence of 
pyrimethamine. 
Allele  Relative growth rate  Standard Error
00000  0.000969794  3.71E-05
00001  0.000884475  9.08E-06
00010  0.000851618  1.35E-05
00020  0.000884462  1.14E-05
00021  0.000903857  2.07E-05
00100  0.000950368  1.99E-05
00101  0.000953728  1.14E-05
00110  0.000969172  1.86E-05
00120  0.000923846  1.77E-06
00111  0.000845918  5.11E-05
00121  0.000953019  1.63E-05
01000  0.000776222  2.42E-05
01001  0.000821543  4.13E-05
01010  0.000906315  2.33E-05
01011  0.000693783  5.65E-05
01021  0.000730816  1.53E-06
01100  0.000883164  3.53E-05
01101  0.000889632  3.08E-05
01110  0.001005913  1.10E-0501111  0.000867504  3.17E-05
01121  0.000833688  8.17E-05
10020  0.000889515  5.10E-05
10101  0.000763795  4.45E-05
10120  0.000999062  2.95E-05
10121  0.000812232  6.95E-08
11020  0.000904206  5.88E-06
11100  0.000811488  5.01E-05
11120  0.000960132  2.11E-05
11121  0.000852969  4.10E-05Supplementary Table S3. Inhibitory Concentration 50 (IC50) values for all 29 functional 
DHFR alleles.
Allele  log10 (IC50) (M)  Standard Error
00000  -6.286287875  0.052603864
00001  -5.811815501  0.01306476
00010  -4.238783454  0.014037526
00020  -4.48211461  0.026490422
00021  -4.612314599  0.012289668
00100  -6.045979852  0.035257835
00101  -5.774205882  0.019191452
00110  -3.732112289  0.024631581
00120  -3.777079714  0.051763537
00111  -3.55  0.033087565
00121  -4.14270295  0.011584965
01000  -5.723515651  0.028592668
01001  -5.490538213  0.029968476
01010  -4.015207365  0.017167894
01011  -4.6  0.033087565
01021  -3.816615387  0.021366234
01100  -5.77259696  0.027573359
01101  -5.624057326  0.034434229
01110  -3.587469416  0.116303605
01111  -3.3  0.03308756501121  -3.839352219  0.062476174
10020  -5.915408591  0.033490392
10101  -5.668197909  0.032062366
10120  -5.89185912  0.037337574
10121  -4.822049854  0.016719358
11020  -5.55226339  0.027819595
11100  -6.171380353  0.076834
11120  -5.345615847  0.019982089
11121  -4.655746831  0.017233065Supplementary Table S4. Median Minimum Inhibitory Concentrations (MIC) for each allele, 
as determined by solid plate assay. 
Allele  MIC (M)  Standard Deviation
00000  1.00E-07  1.43E-07
00001  2.50E-07  1.24E-07
00010  2.50E-05  8.84E-06
00020  2.50E-06  1.44E-06
00021  8.75E-06  8.98E-06
00100  2.50E-07  1.54E-07
00101  7.50E-07  1.16E-07
00110  2.00E-04  4.63E-05
00111  2.00E-04  1.125E-04
00120  2.000E-04  1.27E-04
00121  2.500E-05  1.34E-05
01000  5.000E-07  1.34E-07
01001  1.000E-06  7.5E-07
01010  5.000E-05  1.16E-05
01011  1.000E-05  1.71E-13
01021  4.250E-06  4.60E-06
01100  1.000E-06  6.94E-07
01101  1.000E-06  7.75E-07
01110  2.000E-04  5.53E-05
01111  4.000E-04  2.24E-0401121  2.000E-04  4.88E-05
10020  5.500E-08  4.81E-08
10101  5.500E-08  4.84E-07
10110  5.000E-10  7.07E-10
10120  6.250E-07  3.81E-07
10121  2.500E-06  1.66E-06
11020  7.500E-07  3.79E-07
11100  5.050E-07  5.74E-07
11120  5.500E-07  6.36E-07
11121  1.000E-05  9.75E-06